Clinical Trials Directory

Trials / Completed

CompletedNCT00289874

Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)

A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients With Seasonal Aeroallergen Sensitivity

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
421 (actual)
Sponsor
Organon and Co · Industry
Sex
All
Age
6 Years – 14 Years
Healthy volunteers
Not accepted

Summary

This is a 3-week study to evaluate FEV1 following treatment with drugs in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.

Conditions

Interventions

TypeNameDescription
DRUGmontelukast sodiummontelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
DRUGComparator: PlaceboPlacebo. Up to 3 weeks of treatment

Timeline

Start date
2006-03-01
Primary completion
2007-07-01
Completion
2007-07-01
First posted
2006-02-10
Last updated
2022-02-02
Results posted
2010-10-01

Source: ClinicalTrials.gov record NCT00289874. Inclusion in this directory is not an endorsement.

Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED) (NCT00289874) · Clinical Trials Directory